ARTICLE | Clinical News
CeaVac monoclonal antibody vaccine regulatory update
January 4, 2000 8:00 AM UTC
TTP received U.S. Patent No. 5,977,315 covering CeaVac and its use in generating immune responses to carcinoembryonic antigen. ...
TTP received U.S. Patent No. 5,977,315 covering CeaVac and its use in generating immune responses to carcinoembryonic antigen. ...